India Oligonucleotides Synthesis Market - Industry Trends and Forecast to 2030

TABLE OF CONTENT

1 INTRODUCTION 10
1.1 OBJECTIVES OF THE STUDY 10
1.2 MARKET DEFINITION 10
1.3 OVERVIEW OF THE INDIA OLIGONUCLEOTIDES SYNTHESIS MARKET 10
1.4 LIMITATIONS 11
1.5 MARKETS COVERED 12
2 MARKET SEGMENTATION 14
2.1 MARKETS COVERED 14
2.2 GEOGRAPHICAL SCOPE 15
2.3 YEARS CONSIDERED FOR THE STUDY 15
2.4 CURRENCY AND PRICING 15
2.5 Cognate Lifesciences TRIPOD DATA VALIDATION MODEL 16
2.6 MULTIVARIATE MODELLING 19
2.7 PRODUCT TYPE LIFELINE CURVE 19
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
2.9 Cognate Lifesciences MARKET POSITION GRID 21
2.10 MARKET END USER COVERAGE GRID 22
2.11 VENDOR SHARE ANALYSIS 23
2.12 SECONDARY SOURCES 24
2.13 ASSUMPTIONS 24
3 EXECUTIVE SUMMARY 25
4 PREMIUM INSIGHTS 27
4.1 PESTEL ANALYSIS 28
4.2 PORTER’S FIVE FORCES 29
4.3 PRICING STRATEGY 30
4.4 INDIA OLIGONUCLEOTIDES SYNTHESIS MARKET, CONJOINT ANALYSIS 31
4.4.1 FEATURE- CUSTOMIZATION 31
4.4.2 FEATURE- ADDITIONAL SERVICES 32
5 REGULATORY COMPLIANCE 33
5.1 REGULATORY AUTHORITIES: 33
5.2 REGULATORY SCENARIO IN INDIA - 33
6 MARKET OVERVIEW 35
6.1 DRIVERS 37
6.1.1 USE OF SYNTHESIZED OLIGONUCLEOTIDES IN VARIOUS APPLICATIONS 37
6.1.2 INCREASING GOVERNMENT INVESTMENTS AND R&D EXPENDITURE 37
6.2 RESTRAINTS 38
6.2.1 RISING COMPETITION AMONG MARKET PLAYERS 38
6.2.2 LACK OF TRAINED PROFESSIONALS 38
6.3 OPPORTUNITY 39
6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS 39
6.4 CHALLENGE 39
6.4.1 LIMITATION OF OLIGONUCLEOTIDES SYNTHESIS 39
7 INDIA OLIGONUCLEOTIDES SYNTHESIS MARKET, BY TYPE 40
7.1 OVERVIEW 41
7.2 CUSTOM OLIGOS 42
7.3 PREDESIGNED OLIGOS 42
8 INDIA OLIGONUCLEOTIDES SYNTHESIS MARKET, BY PRODUCT TYPE 43
8.1 OVERVIEW 44
8.2 EQUIPMENT'S 45
8.2.1 OLIGOSYNTHESIZER 45
8.2.1.1 SMALL SCALE SYNTHESIS 46
8.2.1.2 MEDIUM SCALE SYNTHESIS 46
8.2.1.3 LARGE SCALE SYNTHESIS 46
8.2.2 COMPUTER-CONTROLLED INSTRUMENTS 46
8.2.2.1 COLUMN FORMAT 46
8.2.2.2 MULTI-WELL PLATE FORMAT 46
8.3 REAGENTS, CONSUMABLES & ACCESSORIES 47
8.3.1 CAPPING REAGENTS 47
8.3.2 ACTIVATOR SOLUTION 48
8.3.2.1 ACTIVATOR SOLUTION (DCI) 48
8.3.2.2 ACTIVATOR SOLUTION (ETT) 48
8.3.2.3 ACTIVATOR SOLUTION (BTT) 48
8.3.2.4 OTHERS 48
8.3.3 OXIDIZER 49
8.3.4 DEBLOCK SOLUTION 49
8.3.4.1 DEBLOCK DCM SOLUTION 49
8.3.4.2 DEBLOCK DCE SOLUTION 49 
8.3.5 COUPLING 50
8.3.5.1 ANHYDROUS ACETONITRILE 50
8.3.5.2 ACTIVATORS 50
8.3.6 DEPROTECTED REAGENTS 50
8.3.7 OTHERS 50
9 INDIA OLIGONUCLEOTIDES SYNTHESIS MARKET, BY SYNTHESIS METHOD 51
9.1 OVERVIEW 52
9.2 SOLID PHASE OLIGO SYNTHESIS METHOD 53
9.2.1 COLUMN-BASED OLIGONUCLEOTIDE SYNTHESIS 53
9.2.2 MICROARRAY-BASED OLIGONUCLEOTIDE SYNTHESIS 53
9.3 LIQUID/ENZYMATIC PHASE OLIGO SYNTHESIS METHOD 54
9.3.1 TEMPLATE INDEPENDENT POLYMERASE-BASED METHOD 54
9.3.2 TEMPLATE-DEPENDENT POLYMERASE MEDIATED OLIGO SYNTHESIS 54
10 INDIA OLIGONUCLEOTIDES SYNTHESIS MARKET, BY APPLICATION 55
10.1 OVERVIEW 56
10.2 DIAGNOSTICS 57
10.2.1 INFECTIOUS DISEASES 57
10.2.2 CANCER 57
10.2.3 NEUROLOGICAL DISEASE 58
10.2.4 CARDIOVASCULAR DISEASE 58
10.2.5 OTHERS 58
10.3 THERAPEUTICS 58
10.3.1 RNAI OLIGONUCLEOTIDE-BASED THERAPIES 58
10.3.2 DNA/ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES 58
10.3.3 IMMUNOTHERAPY (CPG OLIGONUCLEOTIDE-BASED THERAPIES) 59
10.3.4 NUCLEIC ACID APTAMERS 59
10.4 RESEARCH 59
10.4.1 APTAMER DESIGN 59
10.4.2 ALLELE-SPECIFIC TESTING 59
10.4.3 TRIPLEX-FORMING OLIGONUCLEOTIDES 59
10.4.4 OTHER RESEARCH APPLICATIONS 59
10.5 AGRICULTURE 60
10.6 FOOD 60
10.7 OTHERS 60 
11 INDIA OLIGONUCLEOTIDES SYNTHESIS MARKET, BY END USER 61
11.1 OVERVIEW 62
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 63
11.3 DIAGNOSTIC CENTERS 63
11.4 CONTRACT RESEARCH ORGANIZATION 63
11.5 RESEARCH & ACADEMIC INSTITUTES 63
11.6 FORENSIC LABS 63
12 INDIA OLIGONUCLEOTIDES SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL 64
12.1 OVERVIEW 65
12.2 DIRECT TENDER 66
12.3 RETAIL SALES 66
12.4 OTHERS 66
13 INDIA OLIGONUCLEOTIDES SYNTHESIS MARKET, COMPANY LANDSCAPE 67
13.1 COMPANY SHARE ANALYSIS: INDIA 67
14 COMPANY PROFILE 68
14.1 THERMO FISHER SCIENTIFIC 68
14.1.1 COMPANY SNAPSHOT 68
14.1.2 REVENUE ANALYSIS 68
14.1.3 PRODUCT PORTFOLIO 69
14.1.4 RECENT DEVELOPMENTS 69
14.2 AGILENT TECHNOLOGIES INC 70
14.2.1 COMPANY SNAPSHOT 70
14.2.2 REVENUE ANALYSIS 70
14.2.3 PRODUCT PORTFOLIO 71
14.2.4 RECENT DEVELOPMENTS 71
14.3 MERCK KGAA 72
14.3.1 COMPANY SNAPSHOT 72
14.3.2 REVENUE ANALYSIS 72
14.3.3 PRODUCT PORTFOLIO 73
14.3.4 RECENT DEVELOPMENT 73
14.4 DANAHER 74
14.4.1 COMPANY SNAPSHOT 74
14.4.2 REVENUE ANALYSIS 74
14.4.3 PRODUCT PORTFOLIO 75
14.4.4 RECENT DEVELOPMENT 75 
14.5 LGC LIMITED 76
14.5.1 COMPANY SNAPSHOT 76
14.5.2 PRODUCT PORTFOLIO 76
14.5.3 RECENT DEVELOPMENT 76
14.6 AJINOMOTO BIO-PHARMA 77
14.6.1 COMPANY SNAPSHOT 77
14.6.2 PRODUCT PORTFOLIO 77
14.6.3 RECENT DEVELOPMENT 77
14.7 EUROFINS GENOMICS 78
14.7.1 COMPANY SNAPSHOT 78
14.7.2 PRODUCT PORTFOLIO 78
14.7.3 RECENT DEVELOPMENT 78
14.8 GENERAL ELECTRIC 79
14.8.1 COMPANY SNAPSHOT 79
14.8.2 REVENUE ANALYSIS 79
14.8.3 PRODUCT PORTFOLIO 80
14.8.4 RECENT DEVELOPMENT 80
14.9 METTLER TOLEDO INDIA PRIVATE LTD 81
14.9.1 COMPANY SNAPSHOT 81
14.9.2 PRODUCT PORTFOLIO 81
14.9.3 RECENT DEVELOPMENT 81
14.10 TRILINK BIOTECHNOLOGIES, LLC 82
14.10.1 COMPANY SNAPSHOT 82
14.10.2 PRODUCT PORTFOLIO 82
14.10.3 RECENT DEVELOPMENT 82
15 QUESTIONNAIRE 83
16 RELATED REPORTS 86